Markers and Calculation of Cardiovascular Risk in the Distinct Phenotypes of Polycystic Ovary Syndrome

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01392781

Enrollment

300

Registered

2011-07-13

Start date

2011-04-30

Completion date

2012-01-31

Last updated

2011-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic Ovary Syndrome

Keywords

PCOS, hsC-RP, Lp-PLA2, cardiovascular risk

Brief summary

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder and cause of anovulatory infertility among reproductive aged women. According to the revised criteria of 2003, four distinct phenotypes of PCOS can be diagnosed. However, there are emerging evidence supporting the existence of different levels of cardiometabolic risk between the four phenotypic groups of the syndrome. The purpose of this study is to determine the cardiovascular risk of i) normoweight and ii)overweight plus obese women of every one of the four phenotypes of the syndrome as well as the levels of low inflammation serum markers and the possible correlations of the between the outcomes.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

15 Years to 35 Years

Healthy volunteers

Yes

Inclusion criteria

* Diagnosis of PCOS (criteria 2003) * Healthy controls

Exclusion criteria

* any condition mimicking PCOS * any systematic disease

Design outcomes

Primary

Measure	Time frame
high sensitivity C-Reactive Protein (hsC-RP) levels and differences between the phenotypes	1 hour
Lipoprotein-associated phospholipase2 (Lp-PLA2) levels and differences between the phenotypes	1 hour
Cardiovascular Risk Assessment and differences between the phenotypes	1 hour

Countries

Greece

Contacts

Primary ContactGeorgios Daskalopoulos, M.D.

daskalog@gmail.com

Outcome results